XT
AUPH icon

XTX Topco’s Aurinia Pharmaceuticals AUPH Stock Holding History

XTX Topco’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-177,381
Closed -$2.63M – 4142
2026
Q1 		$2.63M Buy
+177,381
New +$2.59M 0.05% 646
2025
Q4 		– Sell
-21,686
Closed -$240K – 3313
2025
Q3 		$240K Buy
+21,686
New +$237K 0.01% 1693
2025
Q2 		– Sell
-106,435
Closed -$856K – 2345
2025
Q1 		$856K Buy
106,435
+63,681
+149% +$516K 0.04% 657
2024
Q4 		$384K Buy
+42,754
New +$349K 0.03% 1003
2024
Q2 		– Sell
-23,491
Closed -$118K – 1856
2024
Q1 		$118K Buy
+23,491
New +$159K 0.02% 1332
2023
Q4 		– Sell
-24,261
Closed -$189K – 1578
2023
Q3 		$189K Buy
24,261
+10,700
+79% +$105K 0.03% 1033
2023
Q2 		$131K Buy
+13,561
New +$141K 0.02% 1119
2023
Q1 		– Sell
-68,543
Closed -$296K – 1265
2022
Q4 		$296K Buy
68,543
+35,790
+109% +$208K 0.06% 592
2022
Q3 		$246K Buy
32,753
+19,502
+147% +$169K 0.06% 634
2022
Q2 		$133K Buy
+13,251
New +$148K 0.05% 573

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

XTX Topco's AUPH Position: Q2 2026 in Review

XTX Topco sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2026, closing a stake of 177,381 shares — an estimated $2.63M sold.

XTX Topco first reported a position in AUPH in Q2 2022 and held it in 10 quarters. The position peaked at $2.63M in Q1 2026. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • XTX Topco reported no remaining Aurinia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • XTX Topco sold 177,381 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $2.63M.
  • XTX Topco first reported a position in Aurinia Pharmaceuticals in Q2 2022 and held it in 10 quarters.
  • XTX Topco's Aurinia Pharmaceuticals position peaked at $2.63M in Q1 2026.
  • 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.